Malignant News and Research

RSS

Researchers resolve mysteries about the function of key gene-silencing protein

A long-running debate over how an important gene-silencing protein identifies its targets has been resolved by researchers at Massachusetts General Hospital (MGH).

4 Jan 2021

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

A cancer-specific L-type amino acid transporter 1 (LAT1) is highly expressed in cancer tissues.

4 Jan 2021

New UCLA-developed device transfers mitochondria into 100,000 or more recipient cells

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput method for transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells.

29 Dec 2020

Researchers develop new drug discovery method targeting membrane proteins on live cells

A research team led by Dr Xiaoyu LI from the Research Division for Chemistry, Faculty of Science, in collaboration with Professor Yizhou LI from School of Pharmaceutical Sciences, Chongqing University and Professor Yan CAO from School of Pharmacy, Second Military Medical University in Shanghai has developed a new drug discovery method targeting membrane proteins on live cells.

28 Dec 2020

Researchers discover how shattered chromosomes make cancer cells more aggressive

Cancer is one of the world's greatest health afflictions because, unlike some diseases, it is a moving target, constantly evolving to evade and resist treatment.

23 Dec 2020

Molecular reporters produce fluorescence to expose the allies of tumor cells

Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year.

23 Dec 2020

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Cutaneous T cell lymphomas (CTCLs) are a group of non-Hodgkin lymphomas that develop from T cells and mainly impact the skin with painful lesions.

21 Dec 2020

Novel amorphous nanoparticles can efficiently and selectively kill cancer cells

LMU researchers have developed a novel type of nanoparticle that efficiently and selectively kills cancer cells, thus opening up new therapeutic options for the treatment of tumors.

18 Dec 2020

Researchers develop new nanoparticle that efficiently and selectively kills cancer cells

Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have developed a novel type of nanoparticle that efficiently and selectively kills cancer cells, thus opening up new therapeutic options for the treatment of tumors.

18 Dec 2020

Errant DNA triggers immune system response against cancer

DNA that ends up where it doesn't belong in cancer cells can unleash an immune response that makes tumors more susceptible to immunotherapy, the results of two UT Southwestern studies indicate.

17 Dec 2020

Scientists demonstrate a promising strategy for treating lymphomas

Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.

16 Dec 2020

New analysis method could pave the way for important breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.

11 Dec 2020

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

The team of Eva González-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors.

10 Dec 2020

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Research presents potential therapeutic strategy for reducing age-related diseases

Research findings by a KAIST team provide insight into the complex mechanism of cellular senescence and present a potential therapeutic strategy for reducing age-related diseases associated with the accumulation of senescent cells.

10 Dec 2020

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

COVID-19-related disruptions to cervical cancer screening could increase risk sevenfold, UK case study finds

A new study reveals inequalities in the delay in screening for cervical cancer, and recommends that the screening capacity be increased in addition to giving a higher priority to women who have missed their scheduled visit.

2 Dec 2020

Researchers study SerpinB9 protein that could pave way to new immunotherapy approach

Immunotherapies have transformed the landscape of cancer treatment by allowing physicians to alter or augment patients' immune response to better attack malignant tumors.

2 Dec 2020

Malignant News and Research

Researchers resolve mysteries about the function of key gene-silencing protein

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

New UCLA-developed device transfers mitochondria into 100,000 or more recipient cells

Researchers develop new drug discovery method targeting membrane proteins on live cells

Researchers discover how shattered chromosomes make cancer cells more aggressive

Molecular reporters produce fluorescence to expose the allies of tumor cells

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Novel amorphous nanoparticles can efficiently and selectively kill cancer cells

Researchers develop new nanoparticle that efficiently and selectively kills cancer cells

Errant DNA triggers immune system response against cancer

Scientists demonstrate a promising strategy for treating lymphomas

New analysis method could pave the way for important breakthroughs in immunotherapy

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Research presents potential therapeutic strategy for reducing age-related diseases

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

COVID-19-related disruptions to cervical cancer screening could increase risk sevenfold, UK case study finds

Researchers study SerpinB9 protein that could pave way to new immunotherapy approach

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News